Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

[1]  M. Raaben,et al.  Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling , 2017, Nature.

[2]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[3]  A. Ribas,et al.  What does PD-L1 positive or negative mean? , 2016, The Journal of experimental medicine.

[4]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[5]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[6]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[7]  Deborah S. Barkauskas,et al.  Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity , 2016, Science.

[8]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[9]  Drew M. Pardoll,et al.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. , 2016, The New England journal of medicine.

[10]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[11]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[12]  Daniel H. Lackner,et al.  A generic strategy for CRISPR-Cas9-mediated gene tagging , 2015, Nature Communications.

[13]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[14]  D. Adams,et al.  Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts , 2015, EMBO molecular medicine.

[15]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Borst,et al.  Identification of the Common Origins of Osteoclasts, Macrophages, and Dendritic Cells in Human Hematopoiesis , 2015, Stem cell reports.

[17]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[18]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[19]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[20]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[21]  S. Zheng,et al.  The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. , 2013, Immunity.

[22]  G. Freeman,et al.  Strength of PD-1 signaling differentially affects T-cell effector functions , 2013, Proceedings of the National Academy of Sciences.

[23]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[24]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[25]  A. Murakami,et al.  Identification of CMTM7 as a Transmembrane Linker of BLNK and the B-Cell Receptor , 2012, PloS one.

[26]  J.,et al.  The New England Journal of Medicine , 2012 .

[27]  J. Dye,et al.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.

[28]  Carla P. Guimarães,et al.  Haploid Genetic Screens in Human Cells Identify Host Factors Used by Pathogens , 2009, Science.

[29]  T. Schumacher,et al.  Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. , 2007, Blood.

[30]  Lieping Chen,et al.  Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274) , 2006, FEBS letters.

[31]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[32]  Yingyu Chen,et al.  Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. , 2003, Genomics.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .